Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more
Aminologics Co.Ltd (074430) - Net Assets
Latest net assets as of September 2025: ₩56.08 Billion KRW
Based on the latest financial reports, Aminologics Co.Ltd (074430) has net assets worth ₩56.08 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩83.03 Billion) and total liabilities (₩26.95 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩56.08 Billion |
| % of Total Assets | 67.54% |
| Annual Growth Rate | -0.09% |
| 5-Year Change | -3.48% |
| 10-Year Change | 7.08% |
| Growth Volatility | 29.91 |
Aminologics Co.Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Aminologics Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aminologics Co.Ltd (2008–2024)
The table below shows the annual net assets of Aminologics Co.Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩51.70 Billion | -4.99% |
| 2023-12-31 | ₩54.41 Billion | +5.85% |
| 2022-12-31 | ₩51.40 Billion | -13.45% |
| 2021-12-31 | ₩59.39 Billion | +10.90% |
| 2020-12-31 | ₩53.56 Billion | +3.29% |
| 2019-12-31 | ₩51.85 Billion | -2.51% |
| 2018-12-31 | ₩53.19 Billion | +17.82% |
| 2017-12-31 | ₩45.14 Billion | +1.33% |
| 2016-12-31 | ₩44.55 Billion | -7.72% |
| 2015-12-31 | ₩48.28 Billion | +51.59% |
| 2014-12-31 | ₩31.85 Billion | -21.22% |
| 2013-12-31 | ₩40.42 Billion | +28.32% |
| 2012-12-31 | ₩31.50 Billion | -48.59% |
| 2011-12-31 | ₩61.27 Billion | +74.53% |
| 2010-12-31 | ₩35.11 Billion | -33.06% |
| 2008-12-31 | ₩52.44 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aminologics Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7399738800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩8.78 Billion | 16.99% |
| Other Components | ₩116.91 Billion | 226.15% |
| Total Equity | ₩51.70 Billion | 100.00% |
Aminologics Co.Ltd Competitors by Market Cap
The table below lists competitors of Aminologics Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GHCL TEXTILES LTD
NSE:GHCLTEXTIL
|
$58.38 Million |
|
BILENDI EO-80
F:830
|
$58.38 Million |
|
Reliance Industrial Infrastructure Limited
NSE:RIIL
|
$58.40 Million |
|
Calitech Co Ltd
TWO:6532
|
$58.40 Million |
|
We & Win Development Co Ltd
TW:2537
|
$58.35 Million |
|
R&B FOOD SUPPLY
BK:RBF-R
|
$58.33 Million |
|
AGILYX ASA NK -02
F:5NQ
|
$58.32 Million |
|
Amoeba SA
PA:ALMIB
|
$58.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aminologics Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 54,411,009,070 to 51,695,321,420, a change of -2,715,687,650 (-5.0%).
- Net loss of 1,620,020,950 reduced equity.
- Other factors decreased equity by 1,095,666,700.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-1.62 Billion | -3.13% |
| Other Changes | ₩-1.10 Billion | -2.12% |
| Total Change | ₩- | -4.99% |
Book Value vs Market Value Analysis
This analysis compares Aminologics Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.80x to 2.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩507.22 | ₩1420.00 | x |
| 2017-12-31 | ₩513.99 | ₩1420.00 | x |
| 2018-12-31 | ₩605.60 | ₩1420.00 | x |
| 2019-12-31 | ₩590.39 | ₩1420.00 | x |
| 2020-12-31 | ₩609.81 | ₩1420.00 | x |
| 2021-12-31 | ₩676.25 | ₩1420.00 | x |
| 2022-12-31 | ₩585.29 | ₩1420.00 | x |
| 2023-12-31 | ₩619.53 | ₩1420.00 | x |
| 2024-12-31 | ₩588.61 | ₩1420.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aminologics Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.65%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.10x
- Recent ROE (-3.13%) is below the historical average (-2.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -25.43% | -228.75% | 0.09x | 1.21x | ₩-11.28 Billion |
| 2015 | -5.85% | -25.69% | 0.20x | 1.14x | ₩-7.65 Billion |
| 2016 | -8.40% | -22.86% | 0.33x | 1.10x | ₩-8.20 Billion |
| 2017 | 1.20% | 3.22% | 0.34x | 1.09x | ₩-3.97 Billion |
| 2018 | 15.03% | 43.34% | 0.32x | 1.07x | ₩2.68 Billion |
| 2019 | -2.32% | -6.33% | 0.33x | 1.11x | ₩-6.39 Billion |
| 2020 | 4.00% | 12.12% | 0.29x | 1.12x | ₩-3.22 Billion |
| 2021 | 9.02% | 23.46% | 0.35x | 1.10x | ₩-579.48 Million |
| 2022 | -14.17% | -26.64% | 0.49x | 1.08x | ₩-12.42 Billion |
| 2023 | 4.48% | 11.66% | 0.36x | 1.06x | ₩-3.00 Billion |
| 2024 | -3.13% | -9.65% | 0.30x | 1.10x | ₩-6.79 Billion |
Industry Comparison
This section compares Aminologics Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aminologics Co.Ltd (074430) | ₩56.08 Billion | -25.43% | 0.48x | $58.36 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |